BEGIN:VCALENDAR VERSION:2.0 PRODID:-//Vrije Universiteit Amsterdam//NONSGML v1.0//EN NAME:Inaugural lecture prof.dr. C.W. Menke - van der Houven van Oordt METHOD:PUBLISH BEGIN:VEVENT DTSTART:20260116T154500 DTEND:20260116T171500 DTSTAMP:20260116T154500 UID:2026/inaugural-lecture-prof-dr@8F96275E-9F55-4B3F-A143-836282E12573 CREATED:20260603T080159 LOCATION:Hoofdgebouw, Aula De Boelelaan 1105 1081 HV Amsterdam SUMMARY:Inaugural lecture prof.dr. C.W. Menke - van der Houven van Oordt X-ALT-DESC;FMTTYPE=text/html:

Zicht op de Patiënt

Improving diagnostics and treatments with molecular imaging

With molecular imaging, we use radioactively labeled substances, so-called tracers, and the PET scan visualizes how these are distribu ted throughout the body. By using a tracer that detects hormone-sensi tive breast cancer, we can, for example, improve diagnostics and prov ide insight into the prognosis. This is what medical oncologist Wille mien Menke-van der Houven van Oordt states in her inaugural lecture.< /p>

This technology also allows us to track labeled drugs in the pa tient and obtain information about optimal uptake in tumors and diffi cult-to-reach areas such as the brain. Such research is of great valu e in the early development of new treatments, quickly determining whi ch drug has the best chance of success. In addition, we are developin g tracers for immune cells, which can visualize the effects of (new) immunotherapies. The latest development concerns the labeling of our newest immunotherapies, namely cell therapies, where we want to under stand how these cells accumulate in tumors.

DESCRIPTION:

Improving diagnostics and treatments with molecular i maging

With molecular imaging, we use radioactively labeled subs tances, so-called tracers, and the PET scan visualizes how these are distributed throughout the body. By using a tracer that detects hormo ne-sensitive breast cancer, we can, for example, improve diagnostics and provide insight into the prognosis. This is what medical oncologi st Willemien Menke-van der Houven van Oordt states in her inaugural l ecture. This technology also allows us to track labeled drugs in the patient and obtain information about optimal uptake in tumors and dif ficult-to-reach areas such as the brain. Such research is of great va lue in the early development of new treatments, quickly determining w hich drug has the best chance of success. In addition, we are develop ing tracers for immune cells, which can visualize the effects of (new ) immunotherapies. The latest development concerns the labeling of ou r newest immunotherapies, namely cell therapies, where we want to und erstand how these cells accumulate in tumors. Zicht op de Patiënt END:VEVENT END:VCALENDAR